Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has received positive results from various preclinical safety studies on its Therapy-07 prescription drug. The studies included acute dermal toxicity, phototoxicity, acute dermal irritation/corrosion and corneal opacity and permeability. The results showed that Therapy-07 respects all known standards in terms of product safety for consumers.
“We are very pleased with the results showing that we are in compliance with regulatory authorities regarding the safety of Therapy-07,” said Jean-Philippe Gravel, President and CEO of Triple Hair. “Collectively, these preclinical results, combined with other clinical data collected to date, continue to support the promise and validity of Therapy-07 for the treatment of androgenic alopecia.”
Triple Hair is currently in the process of completing applications for authorization to begin Phase III clinical trials in Canada, the United States, Europe and India.
Alopecia is an underserved global market, valued at US$7.8 billion in 2021 and estimated to reach US$14.2 billion by 2028.
Triple Hair Group Inc. is a Canadian biotechnology company specializing in developing innovative treatments for men and women suffering from alopecia. Its mission is to provide the underserved market with clinically proven and efficient prescription and over-the-counter treatments for hair regrowth.
The Company also sells its drug-free patented products for preventing hair loss and regaining hair density in mild to moderate cases of alopecia under the brands RIZNTM (www.rizn.ca) for men, and Plenty NaturalTM(www.plentynatural.ca) for women. RIZNTM and Plenty NaturalTM allow hair loss sufferers in their early stages to access effective and natural hair growth solutions without a prescription easily.
For more information, visit the Company’s website, at www.triplehair.ca/investors.